Key Takeaways PFE's non-oncology Q2 outlook includes growth in Vyndaqel and Nurtec alongside mixed vaccine trends. Primary Care faces IRA pricing pressure on Eliquis and softer international demand for Prevnar. Comirnaty's Q1 rebound raises hopes, while Paxlovid and Abrysvo may reflect lower demand.Pfizer (PFE) is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which account for around 25% of the company’s total revenues. Pfizer’s key oncology drugs ar ...